(NASDAQ: BRTX) Biorestorative Therapies's forecast annual revenue growth rate of -6.29% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Biorestorative Therapies's revenue in 2024 is $145,800.On average, 1 Wall Street analysts forecast BRTX's revenue for 2024 to be $812,390, with the lowest BRTX revenue forecast at $812,390, and the highest BRTX revenue forecast at $812,390. On average, 1 Wall Street analysts forecast BRTX's revenue for 2025 to be $812,390, with the lowest BRTX revenue forecast at $812,390, and the highest BRTX revenue forecast at $812,390.
In 2026, BRTX is forecast to generate $812,390 in revenue, with the lowest revenue forecast at $812,390 and the highest revenue forecast at $812,390.